Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accentia to raise $8.5 million in financing
The debentures are convertible into company common stock at $1.10 per share. After six months, the debentures will amortize through thirty equal installments. The company may at its
The debentures are convertible into company common stock at $1.10 per share. After six months, the debentures will amortize through thirty equal installments. The company may at its
Subject to final issuance from the Patent and Trademark Office, the newly allowed claims are expected to expire in 2024, taking into account an anticipated patent term adjustment
In addition to the 10-year market exclusivity, incentives relating to the designation include assistance from the European Medicines Evaluation Agency in developing a protocol to maximize the chance
Other owners, Andrew Adkisson and Emily Wilder, will also remain with the company. Mr Adkisson will be responsible for the company’s central fabrication operations and Ms Wilder assumes
The last subject completed her week 24 study visit in early June 2008. This Phase IIb trial (petal study) assesses the impact of elagolix treatment on bone mineral
Preclinical supplies of the drug substance have been recently secured and the preclinical development process is being initiated. The company intends to test the benzoylphenylurea (BPU) agent utilizing
The tests showed that CEL-2000 is equivalent or possibly superior to Enbrel in slowing disease progression and lessening symptoms in mice. In addition, the vaccine has the potential
The new Intego positron emission tomography infusion system is claimed to be the first infusion system available in the US to automate the fluorodeoxyglucose (FDG) delivery process. According
Under the terms of the agreement, effective June 17, 2008, Roche will pay ThromboGenics and BioInvent an upfront payment of E50 million. In addition, ThromboGenics and BioInvent could
The preliminary clinical findings indicate that when used with PET technology, BMS747158 demonstrates a favorable radiation dosimetry profile and is generally well-tolerated. Exploratory analyses from this study showed